American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Protalix BioTherapeutics, Inc. (PLX)

$2.55 -0.78% NYSE: PLX · 15-min delayed

HACKENSACK, New Jersey
Public · NYSE: PLX
226 employees

Visit website Follow

$191.0MMarket cap

$52.7MRevenue · FY2025

-$6.6MNet income

226Employees

PLXNYSE

1996IPO

About Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NYSE: PLX
Employees: 226
IPO date: Jan 2, 1996
Headquarters: 2 UNIVERSITY PLAZA
HACKENSACK, New Jersey 07601
Phone: 201-696-9345
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Wilmington, US
Legal entity ID: 549300SDVB3GP4XDFM60

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Registry IDs

Ticker: PLX NYSE
SEC CIK: 1006281
LEI: 549300SDVB3GP4XDFM60
EIN: 650643773
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Protalix BioTherapeutics, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/protalix-biotherapeutics-inc/"><img src="https://americancompanies.com/badge/protalix-biotherapeutics-inc.svg" alt="Protalix BioTherapeutics, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Protalix BioTherapeutics, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $52.7M
Net income: -$6.6M
Total assets: $82.3M
Market cap: $191.0M

Source: SEC EDGAR · updated Jun 7, 2026

NYSE: PLX

$2.55 -0.78%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$1.67 $3.15

52-week range

Market cap: $191.0M
Shares outstanding: 74.9M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Jan 2, 1996

Protalix BioTherapeutics, Inc. (PLX) Stock Price

Reported a net loss of $6.6M in FY2025.
Trading 19% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Protalix BioTherapeutics, Inc..

Write a review

Newsroom

News about Protalix BioTherapeutics, Inc.

Protalix (PLX) Q2 2026 Earnings Call Transcript The Motley Fool · 2026-08-19 · positive Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) GlobeNewswire Inc. · 2026-03-09 · positive [Latest] Global Fabry Disease Treatment Market Size/Share Worth USD 7.02 Billion by 2034 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) GlobeNewswire Inc. · 2025-03-26 · positive Pluxee to acquire Cobee, an innovative Spanish digital player in Employee Benefits GlobeNewswire Inc. · 2024-06-12 Pluxee signe un accord pour l’acquisition de Cobee, un acteur digital espagnol innovant des avantages aux salariés GlobeNewswire Inc. · 2024-06-12 Pluxee firma un acuerdo para adquirir Cobee, empresa digital e innovadora de origen español especializada en beneficios para empleados GlobeNewswire Inc. · 2024-06-12

News & sentiment via Polygon.io

FAQ

Protalix BioTherapeutics, Inc.: frequently asked questions

Is Protalix BioTherapeutics, Inc. an American company?

Protalix BioTherapeutics, Inc. is a US-based company headquartered in Hackensack, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Protalix BioTherapeutics, Inc. headquartered?

Protalix BioTherapeutics, Inc. is headquartered in Hackensack, New Jersey, United States.

Is Protalix BioTherapeutics, Inc. publicly traded?

Yes — Protalix BioTherapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol PLX on the NYSE.

What does Protalix BioTherapeutics, Inc. do?

Protalix BioTherapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore